Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Sensus Healthcare's 3-Year RORE % for the quarter that ended in Mar. 2026 was 950.00%.
The industry rank for Sensus Healthcare's 3-Year RORE % or its related term are showing as below:
SRTS's 3-Year RORE % is ranked better than 99.36% of 782
companies
in the Medical Devices & Instruments industry
Industry Median: -4.23
vs SRTS: 950.00
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Sensus Healthcare 3-Year RORE % Related Terms
Sensus Healthcare 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Sensus Healthcare's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sensus Healthcare's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sensus Healthcare 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sensus Healthcare's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Sensus Healthcare's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Sensus Healthcare (SRTS) has a 3-Year RORE % of 950.00 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sensus Healthcare and its competitors. According to the industry distribution chart, Sensus Healthcare ranks #5 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 0.59999999999999%.
Is Sensus Healthcare's 3-Year RORE % too high?
Sensus Healthcare's current 3-Year RORE % is 950.00. Based on the distribution chart, Sensus Healthcare ranks #5 out of 782 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sensus Healthcare has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sensus Healthcare's 3-Year RORE % compare to COCH and QTI?
According to the Medical Devices & Instruments industry distribution chart, Sensus Healthcare ranks #5 out of 782 companies for 3-Year RORE %. This places Sensus Healthcare in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Sensus Healthcare and its competitors. Sensus Healthcare's current 3-Year RORE % is 950.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensus Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sensus Healthcare (SRTS) is currently considered Fairly Valued. The stock's GF Value™ is $2.77, compared to a current price of $3.05 — trading 10.1% above its estimated fair value. The current 3-Year RORE % is 950.00. Sensus Healthcare's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Sensus Healthcare (SRTS), the current 3-Year RORE % is 950.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sensus Healthcare (SRTS) Overvalued in 2026?
Based on GuruFocus' analysis, Sensus Healthcare stock appears to be overvalued.
The current stock price of $3.05 is trading 10.1% above its estimated GF Value™ of $2.77.
GuruFocus considers Sensus Healthcare to be Fairly Valued.
Key valuation signals for SRTS:
3-Year RORE %: 950.00
GF Value™: $2.77 vs. price of $3.05 (10.1% above fair value)
No single metric tells the full story. See the SRTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
74GF Score
Get the complete analysis for SRTS
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTS has been successfully added to your 
